MedTrace Logo

Pharmacokinetics of Butyrate Tablet BKR-017

NCT06556745 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2026-04-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetic profile and systemic exposure of BKR-017 in individuals on statin therapy after a single dose and at steady state after seven days repeated twice daily dosing.

Conditions

Interventions

DRUG

BKR-017

BKR-017 is an oral tablet formulation designed to target delivery of sodium butyrate to the colon via colon-targeting technology.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • BioKier Inc.

    lead INDUSTRY

Principal Investigators

  • Frank Greenway, MD · Pennington Biomedical Research Center

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-16
Primary Completion
2025-12-23
Completion
2026-01-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06556745 on ClinicalTrials.gov